# BIO-023 Bio Manufacturing Deviation / CAPA Copilot — Screen

- Date: 2026-08-26
- Status: `KILL GENERIC / ABSORB PROFILE`
- Business number: none
- Purpose: screen whether 2026 manufacturing-AI support signals justify a new bio/pharma quality product.

## Problem signal

2026 manufacturing-AI support programmes explicitly include convergence-bio manufacturing and fund AI applied to real production-process pain points.

Example public signal:

- 2026 Chungbuk Manufacturing AI Field Application Support includes convergence-bio sectors such as medical, bio, cosmetics and food, with AI applied to manufacturing-process problems and on-site validation.
- Source: https://www.bizinfo.go.kr/sii/siia/selectSIIA200Detail.do?pblancId=PBLN_000000000122808

Deviation investigation / CAPA is a real regulated manufacturing pain point, so it was screened as a possible PADIEM evidence/workflow product.

## Current market screen

The generic category is already strongly occupied.

Examples found in the current market:

- Yuktra — GxP manufacturing operating layer with deviations, CAPA, cited SOP answers, audit trail and root-cause hints.
- Qwyn AI — deviation investigation, 6M root-cause hypothesis engine, CAPA and traceable audit workflow.
- ReveonAI — human-in-the-loop pharma quality/manufacturing agents for deviations, CAPA, batch release, audits and regulatory response.
- Causix — GMP deviation intelligence using prior CAPAs, SOPs and batch context.
- DeviationIQ — AI-generated deviation investigation, root cause, 5 Whys and CAPA workflow.
- Lumis / Mareana — source-attributed batch genealogy and investigation copilot.

Representative sources:

- https://www.yuktra.ai/
- https://qwynai.com/
- https://www.reveonai.com/
- https://www.causix.ai/
- https://www.deviationiq.com/
- https://mareana.com/lumis/

The product jobs already marketed include:

```text
deviation intake
→ historical case search
→ root-cause hypotheses
→ SOP / batch / LIMS evidence retrieval
→ CAPA draft
→ audit trail / QA review
→ closure support
```

That is too close to the generic candidate.

## PADIEM-specific remainder

Do not build another pharma CAPA copilot.

If a real manufacturing partner later appears, reuse B48-style verification as a bounded profile such as:

```text
claimed root cause / CAPA effectiveness
→ exact source records
→ batch / SOP / sensor / QC evidence
→ contradiction / missing-evidence check
→ human QA decision
```

Even this should be partner-led because credible GMP workflow requires real domain rules, validation and site data.

## Final disposition

```text
REAL_PROBLEM_SIGNAL = YES
MARKET_OCCUPANCY = HIGH
PADIEM_GENERIC_DIFFERENTIATION = LOW
PARTNER_LED_VERIFICATION_PROFILE = POSSIBLE
STANDALONE_BUILD = NO
DISPOSITION = KILL_GENERIC / ABSORB_B48_PROFILE
```

Preserve this record so generic `AI CAPA / pharma deviation copilot` is not proposed again as a new Business.
